3 / 3
Page 24
Notes:
Joint Event
November 29-30, 2019 | Frankfurt, Germany
28
th
International Conference on
3
rd
International Conference on
Diabetes and Endocrinology
Diabetes and Metabolism
&
2
0
1
9
CONGRESS
DIABETES
2019
DIABETES
Journal of Endocrine Disorders & Surgery | Volume 3
Development of therapeutic drug for type 1 diabetes
Kazuichi Nakamura
Kitasato University, Japan
A
utoimmune diseases are classified into two types; Th1
type and Th2 type in both of which Th1/Th2 balance is
skewedtoeitherside.WeaimedtonormalizetheskewedTh1/
Th2 balance in type 1 diabetes, one of Th1 type autoimmune
diseases. Some foreign protein derived from living organism
with a code number KVT-1 was injected along with adjuvant
to NOD mice, a murine model for type 1 diabetes, at 4 weeks
of age. We successfully inhibited lymphocyte infiltration in
and around pancreatic islets in NODmice after administration
of KVT-1. Even single dose of KVT-1 worked with adjuvant.
Thetargetmechanismofcurrentmarketedimmunomodulatory
drugs is to deplete T lymphocytes in inflammation lesions or
to suppress inflammatory cytokines. These drugs may cause
infectiousdiseases. KVT-1,however,doesnotposesuchconcern,
because KVT-1 is intended to simply normalize the immune
system from the skewed Th1/Th2 balance in type 1 diabetes.
KVT-1 is a group of large molecule foreign antigens to humans
as well as to mice. Allergic responses may be generated in
clinical setting. KVT-1 would be formulated with adjuvant not
to enhance immunological reactions but to sustain gradual
release of KVT-1 from the local injection site, which should
prevent anaphylaxis in the patients. No IgE class antibody
against KVT-1 was detected in NOD mice after single dose
along with adjuvant.
KVT-1 can be a curative medicine for type 1 diabetes which
is unmet need of the therapy. Although the anaphylaxis risk
is considered to be minimum if KVT-1 is administered once
along with adjuvant, it is preferable to identify the most
effective part (epitope) of KVT-1 and to downsize its body. In
addition, the combination therapy with another class of drug
is expected to be more effective.
Speaker Biography
KazuichiNakamurahasexperience inworkingforapharmaceuticalcompany
for about 25 years. His specialization area is immunotoxicology. He started
his current career in researching and teaching in the veterinary school, 2014.
Since then, he has been being enthusiastic to develop therapeutic drugs
for autoimmune diseases based on his experience in drug development
and his knowledge in immunology. KVT-1 is one of the results of his
research over the past 5 years in Kitasato University. He does not think that
immunoenhancement cause autoimmune diseases. Immunoenhancement
is a consequence of autoimmune diseases. Therefore he did not take
immunosuppressive approaches, but tried to modulate the immunological
condition behind the disease. As he believes combination therapy is more
effective for remission of type 1 diabetes, he is now seeking for several
opportunities of collaboration. The final goal of his research is obviously to
improve the patients’ quality of life.
e:
kazunaka@vmas.kitasato-u.ac.jp